BIIO Bionovate Technologies Corporation (CE)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 22, 2020, David Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the result of a disagreement between Mr. Gonzalez and our company on any matter relating to our company's operations, policies or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace Mr. Gonzalez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

Mr. Applbaum, age 49, received a Bachelor of Science in Public Administration from the University of Southern California in 1994. He received a Juris Doctor from Thomas Jefferson School of Law in 2000 and has been a practicing attorney since 2002. Mr. Applbaum worked as a prosecutor for the City of San Diego and has been corporate counsel for several publicly traded companies throughout the years. He has helped many of these entities become and remain current with the guidelines set out by OTC Markets. He has worked both in the private and public sector, bringing a unique perspective to his role with the Company. Bionovate Technologies believes that Mr. Applbaum’s educational background and legal experience give him the qualifications and skills necessary to serve as Chief Executive Officer.

There are no family relationship between Mr. Applbaum and any director or executive officer of our company and no related party transactions required to be reported under Item 404(a) of Regulation S-K.